BREAKING NEWS:

Stronger Together
to Fight Rare Disease

Fibrocell has joined with Castle Creek Pharma to deliver new therapies for patients with high unmet need.

Learn More

 

Our proprietary personalized biologics approach

Targeting the underlying cause of diseases affecting the skin and connective tissue to bring relief to patients and their families

Learn More

personalized biologics approach

Our focus on the patient drives everything we do and as a result, our path forward is clear: to develop game-changing cell and gene therapies for localized treatment of the underlying cause of debilitating diseases.

— John Maslowski, President and Chief Executive Officer

Our robust development pipeline of personalized biologics for localized treatment

Applying the unique characteristics of autologous fibroblasts to cell and gene therapies

gene therapy for recessive dystrophic epidermolysis bullosa
FCX-007 offers the potential to address the underlying cause of RDEB by providing high levels of functional Type VII collagen locally to the affected areas.

Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

gene therapy for Localized scleroderma
FCX-013 offers the potential to address the underlying cause of Localized Scleroderma by regulating collagen accumulation at the site of the disease.

Gene Therapy for Localized Scleroderma

gene therapy arthritis
Goal is to deliver a protein therapy locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy.

Gene Therapy Research Program for Arthritis and Related Conditions

 

Photo left: Courtesy of debra–The Dystrophic Epidermolysis Bullosa Research Association of America. Used with permission.

Recent Happenings

Our News and Events

    patient8-287x284 patient14-189x284 patient1-287x284 patient13-228x284 patient12-322x284 inset-patient-RDEB-476-284 patient6-315x284 patient4-322x284